MA38126B1 - 6-((s)-1-{1-[5-(2-hydroxy-éthoxy)-pyridin-2-yl]-1hpyrazol-3-yl}- éthyl)-3h1,3-benzothiazol-2-one comme antagoniste des récepteurs de l’ampa dépendants de tarp-gamma 8 - Google Patents

6-((s)-1-{1-[5-(2-hydroxy-éthoxy)-pyridin-2-yl]-1hpyrazol-3-yl}- éthyl)-3h1,3-benzothiazol-2-one comme antagoniste des récepteurs de l’ampa dépendants de tarp-gamma 8

Info

Publication number
MA38126B1
MA38126B1 MA38126A MA38126A MA38126B1 MA 38126 B1 MA38126 B1 MA 38126B1 MA 38126 A MA38126 A MA 38126A MA 38126 A MA38126 A MA 38126A MA 38126 B1 MA38126 B1 MA 38126B1
Authority
MA
Morocco
Prior art keywords
tarp
dependent
receptor antagonist
amfa
benzothiazol
Prior art date
Application number
MA38126A
Other languages
English (en)
French (fr)
Other versions
MA38126A1 (fr
Inventor
Jon Kevin Reel
Warren Jaye Porter
Jeffrey Michael Witkin
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of MA38126A1 publication Critical patent/MA38126A1/fr
Publication of MA38126B1 publication Critical patent/MA38126B1/fr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
MA38126A 2012-11-27 2013-11-20 6-((s)-1-{1-[5-(2-hydroxy-éthoxy)-pyridin-2-yl]-1hpyrazol-3-yl}- éthyl)-3h1,3-benzothiazol-2-one comme antagoniste des récepteurs de l’ampa dépendants de tarp-gamma 8 MA38126B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261730273P 2012-11-27 2012-11-27
PCT/US2013/070885 WO2014085153A1 (en) 2012-11-27 2013-11-20 6-((s)-1-{1-[5-(2-hydroxy-ethoxy)-pyridin-2-yl]-1h-pyrazol-3-yl}- ethyl)-3h-1,3-benzothiazol-2-one as a tarp-gamma 8 dependent ampa receptor antagonist

Publications (2)

Publication Number Publication Date
MA38126A1 MA38126A1 (fr) 2017-03-31
MA38126B1 true MA38126B1 (fr) 2017-11-30

Family

ID=49753484

Family Applications (1)

Application Number Title Priority Date Filing Date
MA38126A MA38126B1 (fr) 2012-11-27 2013-11-20 6-((s)-1-{1-[5-(2-hydroxy-éthoxy)-pyridin-2-yl]-1hpyrazol-3-yl}- éthyl)-3h1,3-benzothiazol-2-one comme antagoniste des récepteurs de l’ampa dépendants de tarp-gamma 8

Country Status (35)

Country Link
US (1) US8765960B2 (OSRAM)
EP (1) EP2925754B1 (OSRAM)
JP (1) JP6246227B2 (OSRAM)
KR (1) KR101693133B1 (OSRAM)
CN (1) CN104797578B (OSRAM)
AP (1) AP2015008489A0 (OSRAM)
AR (1) AR093527A1 (OSRAM)
AU (1) AU2013352594B2 (OSRAM)
BR (1) BR112015011200A2 (OSRAM)
CA (1) CA2889243C (OSRAM)
CL (1) CL2015001419A1 (OSRAM)
CR (1) CR20150267A (OSRAM)
CY (1) CY1118657T1 (OSRAM)
DK (1) DK2925754T3 (OSRAM)
DO (1) DOP2015000113A (OSRAM)
EA (1) EA026686B1 (OSRAM)
ES (1) ES2618260T3 (OSRAM)
HR (1) HRP20170274T1 (OSRAM)
HU (1) HUE033447T2 (OSRAM)
IL (1) IL238831B (OSRAM)
JO (1) JO3225B1 (OSRAM)
MA (1) MA38126B1 (OSRAM)
MX (1) MX356478B (OSRAM)
MY (1) MY177721A (OSRAM)
PE (1) PE20151728A1 (OSRAM)
PH (1) PH12015501154B1 (OSRAM)
PL (1) PL2925754T3 (OSRAM)
PT (1) PT2925754T (OSRAM)
SG (1) SG11201504164VA (OSRAM)
SI (1) SI2925754T1 (OSRAM)
TN (1) TN2015000200A1 (OSRAM)
TW (2) TW201825484A (OSRAM)
UA (1) UA114345C2 (OSRAM)
WO (1) WO2014085153A1 (OSRAM)
ZA (1) ZA201503733B (OSRAM)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201609719A (zh) * 2014-05-28 2016-03-16 美國禮來大藥廠 作為TARP-γ8依賴性AMPA受體拮抗劑之6-經取代-3H-1,3-苯并噻唑-2-酮化合物
AU2016255424B2 (en) * 2015-04-29 2020-10-08 Janssen Pharmaceutica Nv Benzimidazolone and benzothiazolone compounds and their use as AMPA receptor modulators
ES2759348T3 (es) 2015-04-29 2020-05-08 Janssen Pharmaceutica Nv Imidazopirazinas y pirazolopirimidinas y su utilización como moduladores de receptores AMPA
ES2865330T3 (es) 2015-04-29 2021-10-15 Janssen Pharmaceutica Nv Azabenzimidazoles y su uso como moduladores del receptor AMPA
ES2767707T3 (es) 2015-04-29 2020-06-18 Janssen Pharmaceutica Nv Compuestos de indolona y su uso como moduladores de receptor AMPA
AU2017350689B2 (en) * 2016-10-26 2021-05-20 Rapport Therapeutics, Inc. Fused bicylic pyridine compounds and their use as AMPA receptor modulators
RU2650523C1 (ru) 2017-07-24 2018-04-16 федеральное государственное автономное образовательное учреждение высшего образования "Казанский (Приволжский) федеральный университет" (ФГАОУ ВО КФУ) Производное пиридоксина для лечения эпилепсии
RU2703286C1 (ru) * 2019-06-18 2019-10-16 федеральное государственное автономное образовательное учреждение высшего образования "Казанский (Приволжский) федеральный университет" (ФГАОУ ВО КФУ) Соли (5-гидрокси-3,4-бис(гидроксиметил)-6-метилпиридин-2-ил)метансульфокислоты и способ их получения

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY132385A (en) * 1995-08-31 2007-10-31 Novartis Ag 2,3-dioxo-1,2,3,4-tetrahydro-quinoxalinyl derivatives
JP2000281676A (ja) * 1999-01-25 2000-10-10 Yamanouchi Pharmaceut Co Ltd Ampa拮抗化合物の新規製造法
KR100850728B1 (ko) * 2000-06-12 2008-08-06 에자이 알앤드디 매니지먼트 가부시키가이샤 1,2-디하이드로피리딘 화합물, 그의 제조 방법 및 그의 용도
US8995993B2 (en) * 2000-10-11 2015-03-31 Gogo Llc System for managing mobile internet protocol addresses in an airborne wireless cellular network
DE602005009021D1 (de) * 2004-12-17 2008-09-25 Lilly Co Eli Neue mch-rezeptorantagonisten
WO2007076161A2 (en) 2005-12-27 2007-07-05 Myriad Genetics, Inc Compounds with therapeutic activity
TW200817385A (en) * 2006-07-04 2008-04-16 Organon Nv Heterocyclic derivatives
WO2010041162A1 (en) * 2008-10-08 2010-04-15 Pfizer Inc. Tetrahydrofuranyl sulfonamides for use as ampa modulators in the treatment of cns disorders
NZ593473A (en) * 2009-01-12 2013-02-22 Pfizer Ltd Sulfonamide derivatives
CN102985420B (zh) * 2010-06-01 2017-07-04 安吉翁生物医药有限公司 细胞色素p450抑制剂及其用途
US9527807B2 (en) * 2011-04-05 2016-12-27 Takeda Pharmaceutical Company Limited Sulfonamide derivative and use thereof
TW201609719A (zh) 2014-05-28 2016-03-16 美國禮來大藥廠 作為TARP-γ8依賴性AMPA受體拮抗劑之6-經取代-3H-1,3-苯并噻唑-2-酮化合物

Also Published As

Publication number Publication date
US8765960B2 (en) 2014-07-01
AR093527A1 (es) 2015-06-10
CN104797578A (zh) 2015-07-22
EP2925754B1 (en) 2016-12-28
BR112015011200A2 (pt) 2017-07-11
UA114345C2 (uk) 2017-05-25
KR101693133B1 (ko) 2017-01-04
CY1118657T1 (el) 2017-07-12
HRP20170274T1 (hr) 2017-04-07
ZA201503733B (en) 2017-09-27
TW201434834A (zh) 2014-09-16
PH12015501154A1 (en) 2015-08-10
AU2013352594B2 (en) 2016-02-18
AU2013352594A1 (en) 2015-06-04
HK1209116A1 (en) 2016-03-24
SG11201504164VA (en) 2015-07-30
CA2889243A1 (en) 2014-06-05
PE20151728A1 (es) 2015-12-02
JO3225B1 (ar) 2018-03-08
DK2925754T3 (en) 2017-02-20
CN104797578B (zh) 2016-11-23
CR20150267A (es) 2015-09-16
IL238831B (en) 2018-08-30
DOP2015000113A (es) 2015-06-15
ES2618260T3 (es) 2017-06-21
MY177721A (en) 2020-09-23
EA026686B1 (ru) 2017-05-31
MX356478B (es) 2018-05-30
TW201825484A (zh) 2018-07-16
CL2015001419A1 (es) 2015-10-02
SI2925754T1 (sl) 2017-02-28
WO2014085153A1 (en) 2014-06-05
TWI618705B (zh) 2018-03-21
IL238831A0 (en) 2015-06-30
PH12015501154B1 (en) 2018-05-30
AP2015008489A0 (en) 2015-05-31
MX2015006697A (es) 2015-08-05
US20140148441A1 (en) 2014-05-29
PL2925754T3 (pl) 2017-07-31
WO2014085153A8 (en) 2014-07-31
JP6246227B2 (ja) 2017-12-13
EP2925754A1 (en) 2015-10-07
EA201590823A1 (ru) 2015-08-31
MA38126A1 (fr) 2017-03-31
JP2016501219A (ja) 2016-01-18
TN2015000200A1 (en) 2016-10-03
KR20150070401A (ko) 2015-06-24
CA2889243C (en) 2017-06-13
HUE033447T2 (en) 2017-11-28
PT2925754T (pt) 2017-02-27

Similar Documents

Publication Publication Date Title
MA38126B1 (fr) 6-((s)-1-{1-[5-(2-hydroxy-éthoxy)-pyridin-2-yl]-1hpyrazol-3-yl}- éthyl)-3h1,3-benzothiazol-2-one comme antagoniste des récepteurs de l’ampa dépendants de tarp-gamma 8
MA32351B1 (fr) Derives d'aminodihydrothiazine a titre d'inhibiteurs de bace pour le traitement de la maladie d'alzheimer
MA37405A1 (fr) Composés hétérocyclyle
MA33492B1 (fr) Inhibiteurs de bace
EA201490912A1 (ru) Производные [1,2,3]триазоло[4,5-d]пиримидина в качестве агонистов каннабиноидного рецептора 2
MA35452B1 (fr) 3-pyrimidin-4-yl-oxazolidin-2-ones comme inhibiteurs d'idh mutante
MA34644B1 (fr) Dérivés de pyrazole aminopyrimidine en tant que modulateurs du lrrk2
MA35434B1 (fr) Amino-quinazolines en tant qu'inhibiteurs de kinase
TW201129555A (en) Process for the manufacture of dabigatrane etexilate
EA201270339A1 (ru) Замещенные производные ксантина
MX2012006909A (es) LIGANDOS DEL RECEPTOR NICOTINICO NEURONAL A4ß2 DE ACETILCOLINA.
MX2009000169A (es) Derivados de purinona como agonistas de hm74a.
UA83875C2 (ru) Производные хинолина для применения в качестве микобактериальных ингибиторов
MA35893B1 (fr) Dérivés d'amide hétérocyclique comme antagonistes du récepteur p2x7
EA200970936A1 (ru) СОЕДИНЕНИЯ ПИРИДО[2,3-d]ПИРИМИДИН-7-ОНА В КАЧЕСТВЕ ИНГИБИТОРОВ PI3K-АЛЬФА ДЛЯ ЛЕЧЕНИЯ РАКА
DE602007012313D1 (de) Als a2b-adenosinrezeptorantagonisten geeignete 5-phenyl-6-pyridin-4-yl-1,3-dihydro-2h-imidazoä4,5-büpyridin-2-onderivate
MX337721B (es) Compuestos de heteroarilo como ligandos del receptor 5-ht4.
TN2014000519A1 (en) Pyrimidinone derivatives as antimalarial agents
MA34663B1 (fr) Composés 3-phénylsulfanylméthyl-bicyclo[3.1.0]hexane 4-substitués en tant qu'antagonistes de mglur 2/3
CY1117011T1 (el) Παραγωγα αζολιου
EA201390327A1 (ru) Гетероциклильные соединения в качестве лигандов гистаминовых hрецепторов
MA33828B1 (fr) Dérivés 8-hydroxyquinoline-7-carboxamide secondaires et leurs utilisations en tant qu'agents antifongiques
PH12013500588A1 (en) Indole derivatives
MX2013005825A (es) Benzoxazepinas como inhibidores de objetivo de rapamicina en mamiferos (mtor) y metodos de uso y fabricacion.
WO2012015687A3 (en) Drug-ligand conjugates, synthesis thereof, and intermediates thereto